Background: Noninvasive assessment of programmed death-ligand 1 (PD-L1) expression status in nonsmall cell lung cancer (NSCLC) is necessary. This study arm to investigate the value of 2-[ 18 F]-fluoro-2deoxy-D-glucose positron emission tomography ( 18 F-FDG PET), diffusion-weighted imaging (DWI), intravoxel incoherent motion (IVIM), and amide proton transfer-weighted imaging (APTWI) in the assessment of PD-L1 status in NSCLC.Methods: This is a prospective diagnostic study. A total of 76 patients with NSCLC underwent chest 18 F-FDG PET/magnetic resonance imaging (MRI). Parameters maximum standardized uptake value (SUV max ), quantitate the metabolic tumor volume (MTV), total lesion glycolysis (TLG), apparent diffusion coefficient (ADC), diffusion coefficient (D), pseudo diffusion coefficient (D*), and perfusion fraction (f), and magnetization transfer ratio asymmetry at 3.5 ppm [MTRasym (3.5 ppm)] from 18 F-FDG PET, DWI, IVIM, and APTWI, respectively, were compared. The optimal combination of parameters was investigated using logistic regression models and evaluated by area under the receiver operating characteristic (ROC) curve (AUC). The bootstrap with 1,000 samples was used for model validation.Results: SUV max , MTV, TLG, and MTRasym (3.5 ppm) were higher and D and f were lower in PD-L1 positive NSCLC than in PD-L1 negative NSCLC (all P<0.05). Logistic analysis showed that the combination of MTRasym (3.5 ppm), D, and SUV max had the strongest predictive value for the differentiation of PD-L1 positive and PD-L1 negative NSCLC [AUC, 0.946; 95% confidence interval (CI): 0.869-0.985; sensitivity, 85.29%; specificity, 91.67%; P all <0.001]. The verification model showed the combination of MTRasym (3.5 ppm), D, and SUV max had the strongest predictive value, and its ROC curve and calibration curve showed good accuracy (AUC, 0.919, 95% CI: 0.891-0.937) and consistency.Conclusions: Multi-parametric 18 F-FDG PET/MRI is beneficial for the non-invasive assessment of PD-L1 status in NSCLC patients, and the combination of SUV max , D, and MTRasym (3.5 ppm) may serve as aThe study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). This prospective study was complied with ethical committee standards and approved by the ethics committee of prognostic biomarker to guide immunotherapy.